Rationale and Dose Regimen for Sitagliptin/ Glimepiride Combination Therapy in Type 2 Diabetes Treatment

Abstract

This study explores how glimepiride, alone or in combination with sitagliptin, affected glycemic control inType 2 diabetes patients. Type 2 diabetes was induced in rats by feeding them a high-fat diet and injectingthem with Alloxan and nicotinamide. Forty-two rats were divided equally into seven groups. Negativecontrol and group 2-7: rats fed with the HFD Positive control (diabetic non-treated) Group (T1, T2, T3, T4and T5) were treated with monotherapy and combination. All the treatment regimen reduces fasting bloodglucose and enhanced GLP-1 and insulin level as indicated by an increase in the area under the curve.Additionally, as opposed to monotherapies, the combination category had better glycemic regulation. As aresult, we assume that sitagliptin/glimepiride combined therapy has a synergistic effect.